Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin

Objective Patients treated with statins for dyslipidemia may still have a residual risk of atherosclerotic cardiovascular disease (ASCVD). To determine whether genetic variants in the cholesteryl ester transport protein (CETP), rs3764261 (C>A), rs708272 (G>A), and rs12149545 (G>A) affect ASCVD risk, we studied the association of these variants with dyslipidemia in statin-treated patients. Patients and Methods We included 299 adult Thai patients treated with a statin (95 men and 204 women). Genotyping was performed by conducting a TaqMan real-time polymerase chain reaction-based analysis. We used logistic regression models adjusted for potential confounders of age, body mass index, blood pressure, insulin resistance, and statin dosage to analyze the association between CETP variants and atherogenic lipoprotein patterns. Results CETP polymorphisms of rs3764261 and rs708272, but not rs12149545, were significantly associated with high-density lipoprotein cholesterol (HDL-C), apoA-I, triglycerides, very low-density lipoprotein (VLDL)-C, and large LDL (LDL1-C) levels as well as mean LDL particle size (all p < 0.020). However, no significant difference was observed in total cholesterol, LDL-C, or apoB levels by CETP variants. Regardless of sex, the combination of rs3764261 (CC genotype) and rs708272 (GG or GA genotypes) showed a stronger association with atherogenic dyslipidemia, including features of decreased HDL-C, elevated triglycerides, and LDL subclass pattern B (odds ratio [OR] = 2.99, 95% confidence interval [CI]: 1.78–5.02) compared with the single variant rs3764261 (OR = 2.11, 95% CI: 1.27–3.50) or rs708272 (OR = 2.12, 95% CI: 1.29–3.49). Conclusion The polymorphisms of CETP rs3764261 (CC genotype) and rs708272 (GG and GA genotypes) may have a higher susceptibility to atherogenic dyslipidemia. Testing for CETP rs3764261 and rs708272 may serve as a surrogate marker for lipid management in statin-treated patients, which may help individualize treatment for reducing the residual risk of ASCVD.

[1]  M. Voevoda,et al.  Association of RS708272 (CETP Gene Variant) with Lipid Profile Parameters and the Risk of Myocardial Infarction in the White Population of Western Siberia , 2019, Biomolecules.

[2]  C. Sukasem,et al.  Association between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone- or clozapine-induced hyperglycemia , 2019, Pharmacogenomics and personalized medicine.

[3]  J. Kai,et al.  Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease , 2019, Heart.

[4]  G. Cai,et al.  Gender specific effect of CETP rs708272 polymorphism on lipid and atherogenic index of plasma levels but not on the risk of coronary artery disease , 2018, Medicine.

[5]  K. Reynolds,et al.  Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol , 2018, Diabetes, obesity & metabolism.

[6]  D. Tate,et al.  Weight gain prevention buffers the impact of CETP rs3764261 on high density lipoprotein cholesterol in young adulthood: The Study of Novel Approaches to Weight Gain Prevention (SNAP). , 2018, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[7]  K. Reynolds,et al.  Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol , 2018, The Journal of clinical endocrinology and metabolism.

[8]  J. Jukema,et al.  CETP (Cholesteryl Ester Transfer Protein) Concentration: A Genome-Wide Association Study Followed by Mendelian Randomization on Coronary Artery Disease , 2018, Circulation. Genomic and precision medicine.

[9]  P. Giral,et al.  Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP. , 2018, Journal of clinical lipidology.

[10]  Dermot F. Reilly,et al.  Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults , 2017, JAMA cardiology.

[11]  Brian A Ference,et al.  Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk , 2017, JAMA.

[12]  Audrey Y. Chu,et al.  Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low‐Density Lipoprotein Cholesterol , 2017, Journal of the American Heart Association.

[13]  Q. Niu,et al.  Association between Six CETP Polymorphisms and Metabolic Syndrome in Uyghur Adults from Xinjiang, China , 2017, International journal of environmental research and public health.

[14]  C. Granger,et al.  Evacetrapib and Cardiovascular Outcomes in High‐Risk Vascular Disease , 2017, The New England journal of medicine.

[15]  H. Swanson,et al.  Current and Emerging Uses of Statins in Clinical Therapeutics: A Review , 2016, Lipid insights.

[16]  Joshua C Denny,et al.  Meta-analysis of genome-wide association studies of HDL cholesterol response to statins , 2016, Journal of Medical Genetics.

[17]  Jennifer Y. Liu,et al.  Metabolic Dyslipidemia and Risk of Coronary Heart Disease in 28,318 Adults With Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl. , 2015, The American journal of cardiology.

[18]  Q. Niu,et al.  Association between Eight Functional Polymorphisms and Haplotypes in the Cholesterol Ester Transfer Protein (CETP) Gene and Dyslipidemia in National Minority Adults in the Far West Region of China , 2015, International journal of environmental research and public health.

[19]  J. Goedecke,et al.  Ethnic differences in the association between lipid metabolism genes and lipid levels in black and white South African women. , 2015, Atherosclerosis.

[20]  W. Niu,et al.  Circulating cholesteryl ester transfer protein and coronary heart disease: mendelian randomization meta-analysis. , 2015, Circulation. Cardiovascular genetics.

[21]  M. Kubo,et al.  Gene-Gene Combination Effect and Interactions among ABCA1, APOA1, SR-B1, and CETP Polymorphisms for Serum High-Density Lipoprotein-Cholesterol in the Japanese Population , 2013, PloS one.

[22]  P. Gu,et al.  CETP gene polymorphisms and risk of coronary atherosclerosis in a Chinese population , 2013, Lipids in Health and Disease.

[23]  J. Spence.  Faculty Opinions recommendation of Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2013 .

[24]  C. Heng,et al.  Association of CETP Taq1B and -629C > A polymorphisms with coronary artery disease and lipid levels in the multi-ethnic Singaporean population , 2013, Lipids in Health and Disease.

[25]  K. Williams,et al.  Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. , 2012, Journal of the American College of Cardiology.

[26]  Markus Abt,et al.  Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[27]  R. Collins,et al.  Statins for people at low risk of cardiovascular disease – Authors' reply , 2012, The Lancet.

[28]  P. Libby,et al.  Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.

[29]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012, The Lancet.

[30]  L. Been,et al.  Genetic variation in cholesterol ester transfer protein, serum CETP activity, and coronary artery disease risk in Asian Indian diabetic cohort , 2012, Pharmacogenetics and genomics.

[31]  F. Magkos,et al.  Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones. , 2011, The Journal of clinical endocrinology and metabolism.

[32]  J. Wouter Jukema,et al.  Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters , 2010, Current medical research and opinion.

[33]  N. Barzilai,et al.  Cholesteryl ester transfer protein (CETP) genotype and reduced CETP levels associated with decreased prevalence of hypertension. , 2010, Mayo Clinic proceedings.

[34]  A. Kontush,et al.  Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors , 2009, European heart journal.

[35]  J. Danesh,et al.  Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. , 2008, JAMA.

[36]  P. Elliott,et al.  Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides , 2008, Nature Genetics.

[37]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[38]  J. Danesh,et al.  Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies , 2007, Circulation.

[39]  B. Horne,et al.  Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease. , 2005, American heart journal.

[40]  B. Horne,et al.  The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. , 2003, American heart journal.

[41]  Alan R. Tall,et al.  Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[42]  A. van Tol,et al.  Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. , 2002, Atherosclerosis.

[43]  L. Heilbronn,et al.  Association between HDL-cholesterol and the Taq1B polymorphism in the cholesterol ester transfer protein gene in obese women. , 2002, Atherosclerosis.

[44]  C. Stancu,et al.  Statins: mechanism of action and effects , 2001, Journal of cellular and molecular medicine.

[45]  J. Mcconnell,et al.  Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. , 2001, Clinical chemistry.

[46]  G. Luc,et al.  Taq1B CETP polymorphism, plasma CETP, lipoproteins, apolipoproteins and sex differences in a Jewish population sample characterized by low HDL-cholesterol. , 2000, Atherosclerosis.

[47]  P. Wilson,et al.  Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[48]  J W Jukema,et al.  The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. , 1998, The New England journal of medicine.

[49]  G. Ponsin,et al.  Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. , 1993, Atherosclerosis.

[50]  A. Tall,et al.  Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.

[51]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[52]  F. Chen,et al.  Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease , 2018 .

[53]  M. Farnier,et al.  Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. , 2000, Arteriosclerosis, thrombosis, and vascular biology.